IASLC World Conference on Lung Cancer | Conference

Sacituzumab Govitecan Generates Responses With Manageable Safety Profile in ES-SCLC

September 9th 2024

Treatment with sacituzumab govitecan in the second-line setting yielded antitumor activity in patients with extensive-stage small cell lung cancer.

Dr Wu on SAFFRON-301 Data in Advanced or Metastatic NSCLC

September 9th 2024

Yi-Long Wu, MD, PhD, discusses findings from the phase 3 SAFFRON-301 trial in patients with advanced or metastatic NSCLC.

Dato-DXd Misses OS End Point in TROPION-Lung01 Study for NSCLC

September 9th 2024

Dato-DXd did not significantly improve overall survival compared with docetaxel for patients with non–small cell lung cancer.

HS-20093 Generates Responses in Pretreated ES-SCLC

September 9th 2024

HS-20093 produced responses in extensive-stage small cell lung cancer after prior platinum-based chemotherapy with or without prior immunotherapy.

Frontline Amivantamab/Lazertinib Combo Shows Trend of OS Benefit in Advanced EGFR+ NSCLC

September 9th 2024

When compared with osimertinib, amivantamab plus lazertinib showed a trend toward favorable overall survival in patients with EGFR-mutant advanced NSCLC.

TROP2 Membrane Ratio Effectively Predicts Dato-DXd Outcomes in NSCLC

September 8th 2024

An exploratory analysis from the TROPION-Lung 01 study shows that positivity for TROP2 normalized membrane ratio can be predictive for improved efficacy in patients with non–small cell lung cancer treated with datopotamab deruxtecan.

Dr Sen on Interim IDeate-Lung01 Data in Extensive-Stage SCLC

September 8th 2024

Triparna Sen, PhD, discusses findings from an interim analysis of the phase 2 IDeate-Lung01 trial in patients with extensive-stage small cell lung cancer.

Patient-Level Data Support Perioperative Nivolumab Use in Resectable NSCLC

September 8th 2024

Event-free survival improved with perioperative nivolumab vs neoadjuvant nivolumab plus chemotherapy in resectable NSCLC, according to a comparison of 2 trials.

Novel Perioperative Combinations Show Efficacy in Resectable NSCLC

September 8th 2024

Several novel combinations yielded high pCR and mPR rates in patients with resectable non–small cell lung cancer, according to data from the 2024 IASLC conference.

Ivonescimab Outperforms Pembrolizumab as Frontline Therapy in PD-L1+ Advanced NSCLC

September 8th 2024

Ivonescimab produced a significant improvement in PFS vs pembrolizumab as frontline therapy in patients with PD-L1–positive advanced NSCLC.

Dr Spira on Updated MARIPOSA Trial Data in EGFR+ Advanced NSCLC

September 8th 2024

Alexander I. Spira MD, PhD, FACP, FASCO, discusses updated findings from the phase 3 MARIPOSA study in EGFR-mutated locally advanced or metastatic NSCLC.

Global Survey Examines Barriers to Optimal Lung Cancer Biomarker Testing

September 8th 2024

Global surveys from 2018 and 2024 demonstrated barriers to optimizing biomarker testing for patients with early- or late-stage lung cancer.

Ifinatamab Deruxtecan Shows Improved Clinical Activity at Higher Dose in ES-SCLC

September 7th 2024

A 12-mg/kg dose of ifinatamab deruxtecan improved efficacy compared with an 8-mg/kg dose in heavily pretreated patients with extensive-stage small cell lung cancer.

Dr Leighl on Amivantamab in Advanced NSCLC With MET Exon 14 Skipping Mutations

September 12th 2023

Natasha B. Leighl, BSc, MMSc, MD, discusses efficacy findings with the EGFR/MET inhibitor amivantamab in patients with advanced non–small cell lung cancer harboring MET exon 14 skipping mutations.

Dr Leal on a PD-L1 Subgroup Analysis of the LUNAR Trial in mNSCLC

September 12th 2023

Ticiana Leal, MD, discusses the rationale for and findings from a PD-L1 subgroup analysis of the phase 3 LUNAR trial in patients with metastatic non–small cell lung cancer.

IMpower151 Misses Primary PFS End Point With Frontline Atezolizumab Plus Bevacizumab/Chemo in NSCLC

September 11th 2023

The addition of atezolizumab to bevacizumab, carboplatin, and pemetrexed or paclitaxel (ABCP) did not result in a statistically significant improvement in progression-free survival vs BCP for patients with metastatic nonsquamous non–small cell lung cancer in the first line, missing the primary end point of the phase 3 IMpower151 study.

Dr Negrao on JDQ443 Plus TNO155 in Advanced, KRAS G12C–Mutated Solid Tumors

September 11th 2023

Marcelo Vailati Negrao, MD, discusses efficacy findings from the phase 1b/2 KontRASt-01 trial (NCT04699188) in patients with KRAS G12C–mutated solid tumors.

Dr Gadgeel on Adagrasib Monotherapy in KRAS G12C–Mutated NSCLC

September 11th 2023

Shirish M. Gadgeel, MD, discusses 2-year follow-up data from the phase 1/2 KRYSTAL-1 trial in patients with advanced or metastatic non–small cell lung cancer harboring KRAS G12C mutations.

Baseline Characteristics Not Tied to Benefit With Durvalumab/Tremelimumab and Chemo in Metastatic NSCLC

September 11th 2023

Treatment with durvalumab plus tremelimumab and chemotherapy led to higher rates of long-term clinical benefit compared with chemotherapy alone in the treatment of patients with first-line metastatic non–small cell lung cancer.

Perioperative Durvalumab Plus Chemo Yields Responses, EFS Benefit in Resectable NSCLC

September 11th 2023

The addition of perioperative durvalumab to neoadjuvant chemotherapy led to a significant improvement in terms of pathological complete response and event-free survival compared with placebo plus chemotherapy in patients with resectable non–small cell lung cancer.